Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.
Also called NCT02501811
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT02501811
-
- Other papers using this trial's data
- Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c-Kit-Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT-HF Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02501811. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2020-06-25 (actual). Results posted on 2021-04-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
- Acronym
- CONCERT-HF
- Condition
- Ischemic Cardiomyopathy
- Intervention (Biological)
- Mesenchymal Stem Cells (MSC)
- Intervention (Biological)
- c-kit+ cells
- Intervention (Biological)
- Placebo (Plasmalyte A)
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct02501811- Content hash
fbe68d86c91da07f1c6df11f63a278fd7f962ae101220be572992cac36309189